"Long-term data from PATHFNDR-1 and PATHFNDR-2 trials show PALSONIFY maintains IGF-1 levels and symptom control. Treatment resulted in stable or reduced pituitary tumor volumes over 48 weeks. Combination therapy with cabergoline showed improved biochemical control in acromegaly patients."